candicidin and Prostatic-Hyperplasia

In a prospective, double-blind, placebo-controlled multicenter study, candicidin (a polyene macrolide) was investigated in the treatment of benign prostatic hypertrophy. Seventy-six patients were included in the study--34 in the candicidin group and 42 in the placebo group. Patients treated with 270 mg. of candicidin daily for 6 months had a significant decrease in residual urine, voided volume and bladder volume. No significant increases were found in flow rates. Symptoms improved significantly in both the candicidin and the placebo group, but no differences in improvement were found between the groups. The results of candicidin treatment are less satisfactory than those following surgery.

Topics: Antifungal Agents; Candicidin; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Time Factors; Urination; Urodynamics

The polyene macrolide candicidin was investigated in the treatment of benign prostatic hyperplasia (BPH). Forty-one unselected patients with BPH and prostatism were admitted to a prospective, double-blind placebo-controlled clinical trial. Patients treated with 270 mg candicidin daily for 6 months had a significant decrease in residual urine and a significant increase in maximum flow rate after correction for differences in corresponding bladder volume. Symptoms improved significantly in both the candicidin and the placebo group but no differences in improvement were found between the two groups. The mechanism of the drug's effect is unknown and positive results are much less pronounced than those obtained with surgery. Candicidin appears valuable in the treatment of BPH patients who are a poor surgical risk.

Topics: Aged; Antifungal Agents; Candicidin; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urodynamics

62 patients with benign prostatic hypertrophy, leading to bladder outflow obstruction, took part in a randomised double-blind trial. Those patients in the treatment group took 6 capsules of a polyene macrolide, candicidin, each day (300 mg daily dose). Subjective improvement was noted in both the treated and the control group. This improvement was not confirmed by pressure flow analysis of micturition. The results of this trial do not support the view that candicidin is a useful drug in the treatment of benign prostatic hypertrophy.

Topics: Aged; Antifungal Agents; Candicidin; Clinical Trials as Topic; Humans; Male; Manometry; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Rheology; Urinary Bladder Neck Obstruction

In a double-blind study, candicidin therapy resulted in over-all clinical improvement of benign prostatic hypertrophy symptoms in 78.1 per cent of treated patients compared with 10 per cent for patients given a placebo. Histologic review of prostates of candicidin-treated patients showed more stroma relative to the epithelium. The epithelium was less active with more cuboidal than columnar cells. There were fewer papillary infoldings, and the epithelium contained more true cysts than did the prostates of patients given a placebo. Urinary testosterone, 17-ketosteroids, 17-hydroxycorticosteroids, and serum androgen, follicle-stimulating hormones, and corticosteroid levels ramained within normal values with candicidin therapy.

Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Antifungal Agents; Candicidin; Circadian Rhythm; Clinical Trials as Topic; Creatinine; Follicle Stimulating Hormone; Humans; Hydrocortisone; Male; Placebos; Prostatic Hyperplasia; Testosterone; Urination Disorders

Forty-three patients with benign prostatic hypertrophy with marked urinary distress, which I believed warranted surgical treatment, were selected from private practice. These patients were treated with long-term conservative therapy to determine the efficacy of candicidin for this condition. Patients receiving candicidin orally 300 mg. per day showed improved subjective symptoms in 89.3 per cent of cases compared to 18.2 per cent for patients treated by placebos. Residual urine was decreased in 85.7 per cent and flow rate was improved in more than 89 per cent of the cases. More than one third of the patients treated with candicidin showed improvement in prostate size compared to none for patients treated with placebos. Occasional gastric upset was the only adverse effect attributed to candicidin, which appears to be a safe and efficacious agent.

Topics: Aged; Candicidin; Humans; Male; Middle Aged; Prostatic Hyperplasia

Topics: Aged; Antifungal Agents; Candicidin; Humans; Male; Middle Aged; Prostatic Hyperplasia

The effect of prolonged oral use of levorin on chromatin from the hypertrophic prostate of old dogs was studied. It was found that the chromatin from the hypertrophic prostate of old animals was characterized by a decrease in the relative content of non-histone proteins, the melting temperature and hyperchromism value. The results of the electrophoretic analysis of the histone fraction composition showed its proteolytic degradation. The matrix activity of chromatin in the RNA-polymerase system remained unchanged. Administration of levorin had no effect on the structural and functional characteristics of the chromatin isolated from the hypertrophic prostate of the old dogs.

Topics: Administration, Oral; Age Factors; Animals; Antifungal Agents; Candicidin; Chromatin; Dogs; Drug Evaluation, Preclinical; Male; Prostate; Prostatic Hyperplasia; Protein Denaturation

The oral treatment of groups of aged BIO 87.20 male hamsters, an inbred line of Syrian hamsters that develops spontaneous cystic prostatic hypertrophy, with either the heptaene macrolide, candicidin, or the bile acid-sequestering anion exchange resin, colestipol, resulted in a significant reduction of prostate size and weight. The effect was most prominent in the high dosage (75 mg per kg per day) candicidin group and moderate in the high dosage (400 mg per kg per day) colestipol group. It was observed microscopically that the extreme dilation of the prostatic acini of the untreated control prostate glands was partially prevented by the treatment, resulting in much less distended prostatic acini. Concomitantly, there was a notable decrease of the total cholesterol content of the entire prostate gland and the plasma of the high dosage candicidin group. The relationship of certain aspects of sterol metabolism and the possible prevention of cystic prostatic hypertrophy in this new experimental animal disease model is discussed. The effect of these drugs on the nutritional state of the animal and on the synthesis and metabolism of androgens from the testis are questions that remain to be answered.

Topics: Animals; Antifungal Agents; Body Weight; Candicidin; Cholesterol; Colestipol; Cricetinae; Disease Models, Animal; Male; Mesocricetus; Organ Size; Polyamines; Prostate; Prostatic Hyperplasia; Testis